PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
Assuming that PDR001, an anti-PD-1 antibody, with imatinib might be effective in advanced
GIST after failure of standard TKI therapies including imatinib, sunitinib, and regorafenib.
In this phase I/II study of PDR001 plus imatinib, it is aimed to evaluate the safety and
efficacy of this regimen as 4th line of treatment in advanced GIST.